These Cas inhibitors — published in two studies — inhibit the activity of several Type V-A and Type I-C CRISPR systems, including several Cas12a orthologs.
The firm said it will use the funds to build its IP portfolio, expand its team, and develop an infrastructure for partners to build on its CRISPR platform.
Inder Verma had been on leave from PNAS since December after three female scientists at the Salk Institute filed a lawsuit claiming gender discrimination.